Kaplan, AL; Confair, DN; Kim, K; Barros-Álvarez, X; Rodriguiz, RM; Yang, Y; Kweon, OS; Che, T; McCorvy, JD; Kamber, DN; Phelan, JP; Martins, LC; Pogorelov, VM; DiBerto, JF; Slocum, ST; Huang, X; Kumar, JM; Robertson, MJ; Panova, O; Seven, AB; Wetsel, AQ; Wetsel, WC; Irwin, JJ; Skiniotis, G; Shoichet, BK; Roth, BL; Ellman, JA. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity Nature, 20 Oct 2022, 610 (7932), 582–591. 19.4 MB. https://doi.org/10.1038/s41586-022-05258-z #(R)-69 LC,MS,NMR,other
Jayakodiarachchi, N; Maurer, MA; Schultz, DC; Dodd, CJ; Gray, AT; Cho, HP; Boutaud, O; Jones, CK; Lindsley, CW; Bender, AM. Evaluation of the indazole analogs of 5-MeO-DMT and related tryptamines as serotonin receptor 2 agonists ACS Med. Chem. Lett., 19 Jan 2024, n/a. 5.7 MB. https://doi.org/10.1021/acsmedchemlett.3c00566 #(R)-69, 22 MS,NMR
Duan, W; Cao, D; Wang, S; Cheng, J. Serotonin 2A receptor (5-HT2AR) agonists: Psychedelics and non-hallucinogenic analogues as emerging antidepressants Chem. Rev., 10 Jan 2024, 124 (1), 124–163. 12.6 MB. https://doi.org/10.1021/acs.chemrev.3c00375 #170